Breast Cancer, Liquid Biopsy, Early Detection
Conditions
Keywords
Breast cancer detection, Breast Cancer Screening, Blood Test, Early Detection
Brief summary
Breast cancer is the most common cancer that spreads beyond the initial layer of tissue it developed in, and grows into surrounding healthy tissue in women worldwide. It is associated with significant illness and death. Identifying the disease in the early stage is important to achieving positive outcomes in response to diagnosis and treatment. The Syantra blood test has been developed over the past 10 years. This test involves examining blood samples to identify and analyze specific information. This information is run through a software program that then potentially identifies the presence of breast cancer in the blood sample. This test has the potential to increase early stage detection of breast cancer. The main goal of this study is to figure out how well the Syantra blood test identifies the presence of breast cancer in women 30-75 years of age. The study will also look at whether things like ethnicity, geography and certain individual characteristics (including breast density and elevated risk of breast cancer development) have an effect on how well the test works. This study will recruit women who are attending a visit at the site who are aged 30-75 who are undergoing testing for the presence of breast cancer as part of their regular screening or planned follow up imaging and/or biopsy. Participants who provide consent and meet eligibility criteria will complete a baseline questionnaire and have their blood drawn before any scheduled procedures. Relevant information will be collected from their medical record at the time of joining the study and will be reviewed and updated within 60 days and then again at 12 months following the baseline blood draw. Participants will not have to do anything after the initial visit where they may sign consent, complete the intake questionnaire and have their blood drawn.
Detailed description
Primary Objective: Determine clinical performance metrics of the Syantra blood test in a population of women 30-75 years of age. Secondary Objectives: Investigate the role of ethnicity, geography, and participant characteristics (including breast density and elevated risk of breast cancer development) on test performance. Investigate tumor characteristics and test development. Study Design: Non-randomized, blinded, non-interventional, longitudinal, multi-center Investigational Device: Syantra blood test Population: Women age 30-75 years testing for the presence of breast cancer as part of regular breast screening or planned follow-up diagnostic imaging and/or biopsy Accrual Goal: 2,000 women Primary Endpoint: Clinical performance of the Syantra blood test in the primary population Procedure: Participants providing consent and meeting eligibility criteria will complete a baseline questionnaire (demographics and medical history) and have their blood drawn prior to surgical procedure or biopsy (if applicable). Participant medical records will be reviewed to collect relevant history, including imaging studies, surgery, and pathology results, along with medical treatments and patient status. Follow-up: Medical records for participants will be reviewed and updated after completion of diagnostic procedures (within 60 days) and at 12 months post baseline blood draw to complete recording of procedures and status, including interval cancers or other newly diagnosed diseases. Participants with incomplete records or follow-up will be reviewed annually for imaging, pertinent medical issues, and/or outcomes for up to 5 years. Biospecimen Retention: De-identified blood samples stored for up to 20 years.
Interventions
None listed
Sponsors
Syantra Inc.
University of Calgary
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. Elevated risk population sub-group: Women at elevated risk undergoing routine screening for breast cancer. A. Asymptomatic Screening Inclusion Criteria * Age ≥ 30 and ≤ 75 * Planned MRI (for women who qualify) and/or planned screening mammogram (and/or breast ultrasound) * Presentation of factor(s) indicating elevated risk for breast cancer development o Factors may include germline genetic mutations known to increase risk of breast cancer, very dense (D) breast tissue, family history, and/or clinical risk assessment and scoring at elevated risk (20% or greater lifetime risk, or 3% or greater 10-year risk assessed at age 40, using the Tyrer-Cuzick model (v.7 or v.8) or 1.67% or greater 5-year breast cancer risk using the BCSC model * Willing and able to give Written Informed Consent and provide a whole blood sample
Exclusion criteria
* Physical breast symptoms or concerns * Current or suspected cancer diagnosis * Prior BI-RADS 3 or higher imaging results in last 12 months * Breast surgery within the previous 12 months (for any reason) or recent breast biopsy (including needle core biopsy) within the last 12 months * Previous history of any cancer, except for non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma) * Previous history of invasive or non-invasive breast cancer * Concomitant or other concurrent anti-cancer therapy * Blood transfusions within the past 3 months * Born biologically male B. Recall Inclusion Criteria * Age ≥ 30 and ≤ 75 * Previous MRI (for women who qualify) and/or screening mammogram (and/or breast ultrasound) indicating follow-up imaging or biopsy recommended * Presentation of factor(s) indicating elevated risk for breast cancer development o Factors may include germline genetic mutations known to increase risk of breast cancer, very dense (D) breast tissue, family history, and/or clinical risk assessment and scoring at elevated risk (20% or greater lifetime risk, or 3% or greater 10-year risk assessed at age 40, using the Tyrer-Cuzick model (v.7 or v.8) or BOADICEA v6.0 or 1.67% or greater 5-year breast cancer risk using the BCSC model. * Willing and able to give Written Informed Consent and provide a whole blood sample
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity | 3 years | Sensitivity (Se) if the test = TP/TP+FN), ratio of true positives to true positives and false negatives |
| Specificity | 3 years | Specificity (Sp) of the test = TN/ (TN+FP), ratio of true negatives to the true negatives and false positives |
Countries
Canada, United Kingdom, United States
Outcome results
None listed